株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

arGEN-X BVの製品パイプライン分析

arGEN-X BV - Product Pipeline Review - 2016

発行 Global Markets Direct 商品コード 251644
出版日 ページ情報 英文 42 Pages
即納可能
価格
本日の銀行送金レート: 1USD=115.27円で換算しております。

2016年12月31日まで 年末キャンペーン割引: Global Markets Direct社発行レポート
ご注意: ショッピングカートでは適用されませんので、割引価格についてはお問い合わせください

Back to Top
arGEN-X BVの製品パイプライン分析 arGEN-X BV - Product Pipeline Review - 2016
出版日: 2016年08月24日 ページ情報: 英文 42 Pages
概要

arGEN-X BVはオランダに本社を置くバイオ製薬企業で、中枢神経系疾患、腫瘍、免疫、代謝疾患、皮膚炎、遺伝疾患などの治療薬を、独自の抗体プラットフォームを利用し開発しています。

当レポートでは、arGEN-X BVにおける治療薬開発パイプラインの現況と各開発段階の比較分析、薬剤標的、作用機序、投与経路、分子タイプ別の治療薬の評価、最新の企業ニュースや発表、後期段階および中止されたプロジェクトに関する情報などを提供しています。

目次

arGEN-X BVの基本情報

  • arGEN-X BVの概要
  • 主要情報
  • 企業情報

arGEN-X BV:R&Dの概要

  • 主な治療範囲

arGEN-X BV:パイプラインのレビュー

  • 開発段階別のパイプライン製品
  • 単剤製品
  • パートナー製品
    • パートナー製品/併用療法モダリティ
  • アウトライセンス製品
    • アウトライセンス製品/併用療法モダリティ

arGEN-X BV:パイプライン製品の概況

  • 臨床段階にあるパイプライン製品
    • 第1相の製品/併用療法モダリティ
  • 初期段階にあるパイプライン製品
    • 前臨床段階の製品/併用療法モダリティ
    • 創薬中の製品/併用療法モダリティ

arGEN-X BV:薬剤プロファイル

  • ARGX-110
  • ARGX-111
  • ARGX-112
  • ARGX-113
  • Monoclonal Antibodies 2 for Undisclosed Indication
  • Monoclonal Antibodies for Genetic Diseases
  • Monoclonal Antibodies 1 for Undisclosed Indication
  • Monoclonal Antibodies for Cancer, Immunology and Metabolic Disorders
  • Monoclonal Antibodies to Block Nav1.7 for Chronic Pain
  • Onco-003

arGEN-X BV:パイプライン分析

  • 標的別
  • 分子タイプ別
  • 作用機序別

arGEN-X BV:最新のパイプライン動向

arGEN-X BV:開発休止中のプロジェクト

arGEN-X BV:本社と子会社の所在地

  • 本社
  • 支社および子会社

付録

図表一覧

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC08123CDB

Summary

Global Markets Direct's, 'arGEN-X BV - Product Pipeline Review - 2016', provides an overview of the arGEN-X BV's pharmaceutical research and development focus.

The report provides comprehensive information on the therapeutics under development by arGEN-X BV, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the pipeline therapeutic landscape of arGEN-X BV
  • The report provides overview of arGEN-X BV including its business description, key facts, and locations and subsidiaries
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report assesses arGEN-X BV's pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report features arGEN-X BV's out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects

Reasons to buy

  • Evaluate arGEN-X BV's strategic position with total access to detailed information on its product pipeline
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for arGEN-X BV
  • Identify potential new clients or partners in the target demographic
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding arGEN-X BV's pipeline depth and focus of pipeline therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • arGEN-X BV Snapshot
    • arGEN-X BV Overview
    • Key Information
    • Key Facts
  • arGEN-X BV - Research and Development Overview
    • Key Therapeutic Areas
  • arGEN-X BV - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
    • Pipeline Products - Partnered Products
      • Partnered Products/Combination Treatment Modalities
    • Pipeline Products - Out-Licensed Products
      • Out-Licensed Products/Combination Treatment Modalities
  • arGEN-X BV - Pipeline Products Glance
    • arGEN-X BV - Clinical Stage Pipeline Products
      • Phase I Products/Combination Treatment Modalities
    • arGEN-X BV - Early Stage Pipeline Products
      • Preclinical Products/Combination Treatment Modalities
  • Discovery Products/Combination Treatment Modalities
    • arGEN-X BV - Drug Profiles
    • ARGX-110
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • ARGX-111
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • ARGX-113
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • ARGX-112
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • ARGX-115
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Monoclonal Antibodies for Cancer, Immunology and Metabolic Disorders
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Monoclonal Antibody for Skin Inflammation
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Monoclonal Antibodies to Block Nav1.7 for Chronic Pain
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • arGEN-X BV - Pipeline Analysis
    • arGEN-X BV - Pipeline Products by Target
    • arGEN-X BV - Pipeline Products by Route of Administration
    • arGEN-X BV - Pipeline Products by Molecule Type
    • arGEN-X BV - Pipeline Products by Mechanism of Action
  • arGEN-X BV - Recent Pipeline Updates
  • arGEN-X BV - Dormant Projects
  • arGEN-X BV - Locations And Subsidiaries
    • Head Office
    • Other Locations & Subsidiaries
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • arGEN-X BV, Key Information
  • arGEN-X BV, Key Facts
  • arGEN-X BV - Pipeline by Indication, 2016
  • arGEN-X BV - Pipeline by Stage of Development, 2016
  • arGEN-X BV - Monotherapy Products in Pipeline, 2016
  • arGEN-X BV - Partnered Products in Pipeline, 2016
  • arGEN-X BV - Partnered Products/ Combination Treatment Modalities, 2016
  • arGEN-X BV - Out-Licensed Products in Pipeline, 2016
  • arGEN-X BV - Out-Licensed Products/ Combination Treatment Modalities, 2016
  • arGEN-X BV - Phase I, 2016
  • arGEN-X BV - Preclinical, 2016
  • arGEN-X BV - Discovery, 2016
  • arGEN-X BV - Pipeline by Target, 2016
  • arGEN-X BV - Pipeline by Route of Administration, 2016
  • arGEN-X BV - Pipeline by Molecule Type, 2016
  • arGEN-X BV - Pipeline Products by Mechanism of Action, 2016
  • arGEN-X BV - Recent Pipeline Updates, 2016
  • arGEN-X BV - Dormant Developmental Projects,2016
  • arGEN-X BV, Subsidiaries

List of Figures

  • arGEN-X BV - Pipeline by Top 10 Indication, 2016
  • arGEN-X BV - Pipeline by Stage of Development, 2016
  • arGEN-X BV - Monotherapy Products in Pipeline, 2016
  • arGEN-X BV - Partnered Products in Pipeline, 2016
  • arGEN-X BV - Out-Licensed Products in Pipeline, 2016
  • arGEN-X BV - Pipeline by Target, 2016
  • arGEN-X BV - Pipeline by Route of Administration, 2016
  • arGEN-X BV - Pipeline by Molecule Type, 2016
  • arGEN-X BV - Pipeline Products by Mechanism of Action, 2016
Back to Top